EFFECTS OF FRG-8813, A NEW TYPE HISTAMINE-H2-RECEPTOR ANTAGONIST, ON VARIOUS EXPERIMENTAL GASTRIC AND DUODENAL LESIONS IN RATS

We examined the anti-ulcer effects of FRG-8813, a new type histamine H-2-receptor antagonist, on various experimental gastric and duodenal lesions in rats. FRG-8813, administered orally, inhibited the formation of lesions dose-dependently in experimental models with the exception of the Shay ulcer model. The anti-ulcer potency of FRG-8813 was 4-10 times greater than that of cimetidine when the ED50 values of both compounds were compared. Famotidine and cimetidine inhibited lesion formation at higher doses than the anti-secretory doses. The anti-ulcer action of FRG-8813, however, appeared at even lower doses than those of anti-secretory action. These results suggest that FRG-8813 is able to prevent lesion formation with anti-secretory action plus other mechanisms unlike typical histamine H-2-receptor antagonists.